SI2819516T1 - Uporaba (1R,5S)-(+)-1-(naftalen-2-IL)-3-azabiciklo(3.1.0)heksana pri zdravljenju stanj na katere vplivajo monoamin nevrotransmiterji - Google Patents

Uporaba (1R,5S)-(+)-1-(naftalen-2-IL)-3-azabiciklo(3.1.0)heksana pri zdravljenju stanj na katere vplivajo monoamin nevrotransmiterji

Info

Publication number
SI2819516T1
SI2819516T1 SI201231745T SI201231745T SI2819516T1 SI 2819516 T1 SI2819516 T1 SI 2819516T1 SI 201231745 T SI201231745 T SI 201231745T SI 201231745 T SI201231745 T SI 201231745T SI 2819516 T1 SI2819516 T1 SI 2819516T1
Authority
SI
Slovenia
Prior art keywords
naphthalen
azabicyclo
hexane
treatment
monoamine neurotransmitters
Prior art date
Application number
SI201231745T
Other languages
English (en)
Inventor
Anthony Alexander Mckinney
Frank Bymaster
Original Assignee
Otsuka America Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka America Pharmaceutical, Inc. filed Critical Otsuka America Pharmaceutical, Inc.
Publication of SI2819516T1 publication Critical patent/SI2819516T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201231745T 2011-07-30 2012-07-27 Uporaba (1R,5S)-(+)-1-(naftalen-2-IL)-3-azabiciklo(3.1.0)heksana pri zdravljenju stanj na katere vplivajo monoamin nevrotransmiterji SI2819516T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161574231P 2011-07-30 2011-07-30
US201113334066A 2011-12-22 2011-12-22
US201213528940A 2012-06-21 2012-06-21
PCT/US2012/000335 WO2013019271A1 (en) 2011-07-30 2012-07-27 Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters
EP12820058.1A EP2819516B1 (en) 2011-07-30 2012-07-27 Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters

Publications (1)

Publication Number Publication Date
SI2819516T1 true SI2819516T1 (sl) 2020-07-31

Family

ID=47629575

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231745T SI2819516T1 (sl) 2011-07-30 2012-07-27 Uporaba (1R,5S)-(+)-1-(naftalen-2-IL)-3-azabiciklo(3.1.0)heksana pri zdravljenju stanj na katere vplivajo monoamin nevrotransmiterji

Country Status (12)

Country Link
EP (1) EP2819516B1 (sl)
CA (1) CA2843847C (sl)
CY (1) CY1122773T1 (sl)
DK (1) DK2819516T3 (sl)
ES (1) ES2779032T3 (sl)
HR (1) HRP20200424T1 (sl)
HU (1) HUE048715T2 (sl)
LT (1) LT2819516T (sl)
PL (1) PL2819516T3 (sl)
PT (1) PT2819516T (sl)
SI (1) SI2819516T1 (sl)
WO (1) WO2013019271A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613943B1 (pt) 2005-07-27 2021-06-22 Otsuka America Pharmaceutical, Inc Composto, composição farmacêutica o compreendendo, usos de um composto e de uma composição farmacêutica, bem como composição neurobiologicamente ativa
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
JP2017502948A (ja) * 2013-12-09 2017-01-26 ニューロバンス・インコーポレイテッドＮｅｕｒｏｖａｎｃｅ， Ｉｎｃ． 新規な組成物
CA3200692A1 (en) 2015-06-17 2016-12-22 Otsuka America Pharmaceutical, Inc. Crystalline compounds
ES2926186T3 (es) 2016-06-28 2022-10-24 Trichomeshell Ltd Una forma de dosificación para vaporización y fumar
WO2018119291A1 (en) * 2016-12-21 2018-06-28 Otsuka America Pharmaceutical, Inc. Synthetic methods
WO2024048782A1 (en) 2022-09-02 2024-03-07 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
BRPI0613943B1 (pt) * 2005-07-27 2021-06-22 Otsuka America Pharmaceutical, Inc Composto, composição farmacêutica o compreendendo, usos de um composto e de uma composição farmacêutica, bem como composição neurobiologicamente ativa

Also Published As

Publication number Publication date
CA2843847C (en) 2021-05-18
EP2819516A4 (en) 2016-01-20
ES2779032T3 (es) 2020-08-13
CY1122773T1 (el) 2021-05-05
HUE048715T2 (hu) 2020-09-28
EP2819516A1 (en) 2015-01-07
PT2819516T (pt) 2020-03-25
LT2819516T (lt) 2020-05-25
EP2819516B1 (en) 2019-12-25
HRP20200424T1 (hr) 2020-09-04
PL2819516T3 (pl) 2020-08-10
WO2013019271A1 (en) 2013-02-07
DK2819516T3 (da) 2020-03-16
CA2843847A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
IN2014CN02616A (sl)
SI2819516T1 (sl) Uporaba (1R,5S)-(+)-1-(naftalen-2-IL)-3-azabiciklo(3.1.0)heksana pri zdravljenju stanj na katere vplivajo monoamin nevrotransmiterji
EP2646019A4 (en) PREPARATION AND USE OF (+) - 1- (3,4-DICHLOROPHENYL) -3-AZABICYCLO- [3.1.0] HEXANE IN THE TREATMENT OF DISEASES AFFECTED BY MONOAMINE-TYPE NEUROTRANSMITTERS
PH12014501108A1 (en) Anti-il-36r antibodies
AP2013007254A0 (en) 4-Aryl-N-phenyl-1,3,5,-triazin-2-amines containinga sulfoximine group
EP2576488A4 (en) PROCESS FOR PRODUCING CIS-1,1,1,4,4,4, -HEXAFLUORO-2-BUTENE
EP2699091A4 (en) 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS
IL230635A (en) An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
SG11201401565TA (en) Novel 1,1,1,4,4,5,5,6,6,6-decafluorohex-2-ene isomer mixtures and uses thereof
HK1192757A1 (zh) 取代的 -芳基- -苯基- -三嗪- -胺
IL232710B (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
HK1206938A1 (en) Process for the preparation of 3-chloro-4,5,6-trifluoro- picolinonitrile 3--456--
EP2720708A4 (en) AIMING AT THE NEUROMUSCULAR END PLATE FOR TREATMENT PURPOSES
IL232194A0 (en) An improved iontophoretic cross-linking mixture for use in the treatment of keratoconus
IL231468A0 (en) 3,1-diaryl-converted heterocyclic pesticides
HUE041320T2 (hu) 1,3-Specifikus intraészterezés
WO2012138653A3 (en) Treatment regimens
EP2994129A4 (en) Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disorders
AU2017202012A1 (en) Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo(3.1.0)hexane in the treatment of conditions affected by monoamine neurotransmitters
UY4159Q (es) Motocicleta
ITFI20100058U1 (it) Telaio bicicletta smontabile "wirebike3".
AU336245S (en) 'Friendly' tunic
IT1401957B1 (it) Composizione per il trattamento dell'acne.
AU2012266V (en) MJ 511.10 Prunus salicina